DELIX THERAPEUTICS: CLOSES OVERSUBSCRIBED $100 MLN SERIES C FINANCING TO ADVANCE ZALSUPINDOLE INTO PHASE II DEVELOPMENT

Reuters · 11/09 12:09

Please log in to view news